Search Results for 'Dapt-Rivaroxaban'

Dapt-Rivaroxaban published presentations and documents on DocSlides.

A ssessment of  D ual antiplatelet therapy versus
A ssessment of D ual antiplatelet therapy versus
by coursion
R. ivaroxaban . I. n atrial . F. ibrillation patie...
A ssessment of  D ual antiplatelet therapy versus
A ssessment of D ual antiplatelet therapy versus
by stefany-barnette
A ssessment of D ual antiplatelet therapy versus...
Dual Antiplatelet Therapy (DAPT) Duration
Dual Antiplatelet Therapy (DAPT) Duration
by tatiana-dople
Dilemma: Recent Trials And Guidelines For. Clinic...
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
by celsa-spraggs
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
by yoshiko-marsland
(EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS....
Rivaroxaban compared with enoxaparin for the prevention of
Rivaroxaban compared with enoxaparin for the prevention of
by luanne-stotts
Alexander T Cohen . On behalf of the MAGELLAN Ste...
Switching from dual antiplatelet therapy with aspirin plus a P2Y
Switching from dual antiplatelet therapy with aspirin plus a P2Y
by brown
12. inhibitor to dual pathway inhibition with asp...
Aspirin in 2022:  A New Aspirin for a New Chapter
Aspirin in 2022: A New Aspirin for a New Chapter
by belinda
March 28, 2022. Disclosures. Present Research/Gran...
Dominick  J.  Angiolillo
Dominick J. Angiolillo
by SunnySeahorse
, MD. , PhD. Professor. of Medicine. Medical Dire...
DUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPY
by mary
(DAPT) . BHAVI SHAH, DNP, APRN, ANP-C. UNIVERSITY ...
Evidence-Based Antiplatelet Therapy Across the ACS Spectrum
Evidence-Based Antiplatelet Therapy Across the ACS Spectrum
by debby-jeon
Evidence-Based Antiplatelet Therapy Across the AC...
What Has Been Tried and What Is True?
What Has Been Tried and What Is True?
by celsa-spraggs
What Has Changed?. Less Stent Thrombosis . With. ...
Sangramento GI associado a PCI
Sangramento GI associado a PCI
by marina-yarberry
Juan Felipe Castillo Schrul. Residente Hemodinâm...
School Life in Australia
School Life in Australia
by trish-goza
Presented By Kiahna Bailey and Paige Herford. Sch...
Reversing Course:  Managing Anticoagulation and Antiplatelet Bleeding
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
by kyle585
Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP....
Review on NOACs Studies Dr.
Review on NOACs Studies Dr.
by BlessedBeyondMeasure
Kourosh. . Sadeghi. Tehran University of medical ...
MAGELLAN Primary efficacy endpoint  at 10 days (DVT, symptomatic PE,
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
by HoneyBun
VTE death. ) for . rivaroxaban. vs. . enoxaparin....
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
by LittleMissPerfect
rivaroxaban. group vs. 1.02% of the vitamin K ant...
Thromboembolic protocols
Thromboembolic protocols
by cecilia
& safe anticoagulant prescribing. July 2020. D...
Rivaroxaban in stable peripheral or carotid artery disease
Rivaroxaban in stable peripheral or carotid artery disease
by basidell
Sonia Anand, on . behalf of the COMPASS Steering C...
Ima  A.  Kusuma , MD, FIHA
Ima A. Kusuma , MD, FIHA
by hirook
“JIH. ” Hospital, Yogyakarta, Indonesia. The U...
Dr. Phil Wells  on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
by yoshiko-marsland
Dr. Phil Wells on behalf of the EINSTEIN CHOICE ...
CAD/PAD in Primary Care CV Risk in Stable Outpatients
CAD/PAD in Primary Care CV Risk in Stable Outpatients
by stefany-barnette
Stratified by Baseline CV Risk Category. Aspirin ...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by alexa-scheidler
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Stroke, Bleeding, and
Stroke, Bleeding, and
by lois-ondreau
Mortality Risks . in . Elderly Medicare Beneficia...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by giovanna-bartolotta
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
New Oral Anticoagulant
New Oral Anticoagulant
by mitsue-stanley
R2 Patcharee Seesongsom. R2 . Sirada. . Phoja...
R eal-world
R eal-world
by liane-varnes
EVI. dence. on . S. troke prevention . I. n pati...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by ellena-manuel
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by debby-jeon
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Novel Oral Anticoagulants
Novel Oral Anticoagulants
by natalia-silvester
(. N. OAC). Dan . Moellentin. , . PharmD. , BCPS,...
Recent  ACS: STEMI, NSTEMI, UA
Recent ACS: STEMI, NSTEMI, UA
by danika-pritchard
Stabilized 1-7 Days Post-Index Event. Exclusions:...
Dual Anti-Platelet Therapy After TAVR?
Dual Anti-Platelet Therapy After TAVR?
by salem
By: Cole Smith PharmD Candidate 2021. University o...
One-month Ticagrelor Monotherapy After     PCI in Acute Coronary Syndromes:
One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes:
by yvonne
Principal Results From the Double-blind, Placebo-c...
SFA Intervention: In for a Penny
SFA Intervention: In for a Penny
by hadley
Michael N. Young, MD, RPVI. Dartmouth-Hitchcock He...
MOACTFCAI DAPTOLBKTBOLILDVCBBORAOV 24
MOACTFCAI DAPTOLBKTBOLILDVCBBORAOV 24
by harper
20 INTRODUCTION M a glycerol molecule attached to ...
MOACTICAI DAPTOLBNTBOLILDYLCTLBBO 21
MOACTICAI DAPTOLBNTBOLILDYLCTLBBO 21
by ariel
30 Patrick Berg Richard W. McCallum Mark Hall Iren...
Department of Clinical Effectiveness
Department of Clinical Effectiveness
by roxanne
V 3 Approved by Executive Committee of the Medical...
Expert Discussion on Antiplatelet for ACS Patients: Controversies for Asian Patients
Expert Discussion on Antiplatelet for ACS Patients: Controversies for Asian Patients
by GratefulHeart
Akhtar . Fajar. . Muzakkir. New ESC NSTEMI Guidel...